EU Clinical Trial 2018-002433-38

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene  Feb 15, 2019

Main objective of the trial: To evaluate the safety and tolerability of QR-421a.

Parties

Sponsors
Countries
BE CA FR US
Keywords
Not available QR-421a Retinitis pigmentosa

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.